The overall goal of the proposed research is to characterize the kinetics of the potentially atherogenic lipoproteins, low density lipoprotein (LDL), in normolipidemic individuals. In hyperlipidemic subjects, an association exists between risk for coronary artery disease (CAD) and a preponderance of small, dense LDL particles, known as atherogenic lipoprotein phenotype B (ALP-B). It has been suggested that the presence of a single gene accounts for this phenotype and the associated elevated levels of triglyceride. In normolipidemic subjects, ALP-B is also associated with increased plasma triglyceride and reduced HDL cholesterol levels. Because the frequency of this gene is the same in normolipidemic and hyperlipidemic subjects, normolipidemic subjects with the ALP-B may also be at increased risk for CAD. Because of the significance of LDL, and its role in the development of CAD, the studies described in this proposal will examine the kinetics of LDL particles in normolipidemic subjects. The hypotheses to be tested are that among subjects with a predominance of small, dense LDL, the size and density distribution of LDL particles are due to: (a) increased production of small, dense LDL particles, and/or (b) decreased catabolism of these particles. Apolipoprotein B (apoB) turnover studies will be performed to test these hypotheses. These studies will use three isotopes (125I, 131I, and 3H- leucine) which will be introduced exogenously and endogenously to trace the appearance and disappearance of apoB into and from the LDL fraction. Multicompartmental models will be developed to analyze the tracer data. Many studies have focused on the metabolism of lipoproteins in hyperlipidemic subjects and have described the heterogeneous nature of all classes of lipoprotein particles. Few metabolic studies however have examined lipoprotein heterogeneity within the normolipidemic population. Although it is accepted that lipoproteins in normolipidemics are heterogeneous, there was little interest in this observation until recently. As in hyperlipidemic individuals, normolipidemic individuals may also be at increased risk for CAD because of the heterogeneity within the LDL fraction. These studies therefore propose to investigate lipoprotein heterogeneity within the LDL fraction by conducting and analyzing a series of lipoprotein turnover studies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29HL049110-04
Application #
2445235
Study Section
Metabolism Study Section (MET)
Project Start
1994-04-01
Project End
1999-06-30
Budget Start
1997-07-01
Budget End
1999-06-30
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Washington
Department
Engineering (All Types)
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Welty, Francine K; Lichtenstein, Alice H; Barrett, P Hugh R et al. (2004) Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes. Arterioscler Thromb Vasc Biol 24:1703-7
Welty, F K; Lichtenstein, A H; Barrett, P H et al. (2000) Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans. Arterioscler Thromb Vasc Biol 20:1807-10
Wolfe, B M; Barrett, P H; Laurier, L et al. (2000) Effects of continuous conjugated estrogen and micronized progesterone therapy upon lipoprotein metabolism in postmenopausal women. J Lipid Res 41:368-75
Burnett, J R; Wilcox, L J; Telford, D E et al. (1999) Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. J Lipid Res 40:1317-27
Parhofer, K G; Barrett, P H; Schwandt, P (1999) Low density lipoprotein apolipoprotein B metabolism: comparison of two methods to establish kinetic parameters. Atherosclerosis 144:159-66
Burnett, J R; Wilcox, L J; Telford, D E et al. (1999) The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs. Endocrinology 140:5293-302
Wilcox, L J; Barrett, P H; Huff, M W (1999) Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res 40:1078-89
Welty, F K; Lichtenstein, A H; Barrett, P H et al. (1999) Human apolipoprotein (Apo) B-48 and ApoB-100 kinetics with stable isotopes. Arterioscler Thromb Vasc Biol 19:2966-74
Riches, F M; Watts, G F; Hua, J et al. (1999) Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 84:2854-61
Wilcox, L J; Barrett, P H; Newton, R S et al. (1999) ApoB100 secretion from HepG2 cells is decreased by the ACAT inhibitor CI-1011: an effect associated with enhanced intracellular degradation of ApoB. Arterioscler Thromb Vasc Biol 19:939-49

Showing the most recent 10 out of 21 publications